EHO360 LLC v. Opalich

CourtDistrict Court, N.D. Texas
DecidedMarch 17, 2023
Docket3:21-cv-00724
StatusUnknown

This text of EHO360 LLC v. Opalich (EHO360 LLC v. Opalich) is published on Counsel Stack Legal Research, covering District Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
EHO360 LLC v. Opalich, (N.D. Tex. 2023).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

EHO360 LLC, § § Plaintiff, § § v. § CIVIL ACTION NO. 3:21-CV-0724-B § NICHOLAS OPALICH and TAMMY § RADCLIFF, § § Defendants. §

MEMORANDUM OPINION AND ORDER Before the Court is Defendants Nicholas Opalich and Tammy Radcliff’s Motion for Summary Judgment (Doc. 105). For the following reasons, the Court DENIES Defendants’ Motion. I. BACKGROUND This dispute concerns the conduct of two executives, Nicholas Opalich and Tammy Radcliff, during and after their employment with Plaintiff EHO360 LLC (“EHO”). EHO alleges Defendants breached their contractual and fiduciary duties, stole EHO’s confidential information, and used the information to start a competing business. See Doc. 42, Second Am. Compl., ¶ 1. A. EHO Hires Opalich and Radcliff EHO is a Pharmacy Benefits Management company and a claims processor. Doc. 106, Defs.’ Br. Supp., 8. In short, EHO manages prescription claims, consolidates billing for clients, and serves as a “connector[] between employers, payers, patients, consumers, members/workers, drug wholesalers, pharmacies, and drug companies.” Id. at 8 & n.2. On February 1, 2019, EHO hired Opalich as its Chief Executive Officer (“CEO”). See Doc. 114, Pl.’s App., 71–82. Opalich and EHO entered into an Executive Employment Agreement (the “Opalich Agreement”), 1 which detailed the terms of Opalich’s employment. See generally id. Opalich was to receive $275,000 base salary

under the contract. Id. at 72. The Opalich Agreement contained a termination provision (“Section 4(d)”) that stated: Beginning on August 1, 2019, if Executive’s employment is terminated by Employer without cause or if Executive resigns for Good Reason, then during the 12-month period commencing on the date of such termination (or such shorter period equal to the remainder of the Term if such termination occurs when there is less than twelve (12) months remaining in the Term), Executive shall be entitled to receive the annual Base Salary . . . .

See id. Thus, “if Opalich was terminated without cause, he would be paid a severance of the Base Salary for the lesser of 12 months or the balance of the Term of the Opalich Agreement (which was set to end on February 1, 2021).” Doc. 106, Defs.’ Br. Supp., 10. Opalich would also be subject to confidentiality, non-solicitation, and non-compete provisions while receiving payments under Section 4(d). Doc. 114, Pl.’s App., 76–78. These provisions were outlined in Section 9 of the Opalich Agreement. Id. Opalich met Radcliff, a consultant for a specialty pharmaceutical company called KemPharm, in March 2020 at a conference. Doc. 106, Defs.’ Br. Supp., 11. Shortly after, Opalich began recruiting Radcliff to join EHO and lead the company’s hospice division. Doc. 113, Pl.’s Resp. Br., 4; Doc. 114, Pl.’s App., 83. Opalich enlisted Cindy Kepler, a marketing consultant, to help Radcliff create a presentation for EHO’s board “[o]n where she believes she can have an immediate impact for EHO.” Doc. 114, Pl.’s App., 83; Doc. 113, Pl.’s Resp. Br., 4–5. The end

1 The Opalich Agreement was executed between Opalich and an EHO affiliate, SPCGT Management, LLC (“SPCGT”). Doc. 42, Second Am. Compl., ¶ 15. SPCGT then “assigned all its rights under the Opalich Agreement to EHO.” Id. product contained a business plan “with short-term and long-term hospice business opportunities Radcliff would pursue if she was hired by EHO.” Doc. 113, Pl.’s Resp. Br., 5; Doc. 114, Pl.’s App., 186. Radcliff presented this to EHO’s board in April 2020. Doc. 113, Pl.’s Resp. Br., 5; Doc. 114,

Pl.’s App., 21–24. Kepler invoiced EHO for her work on the presentation. Doc. 113, Pl.’s Resp. Br., 5; Doc. 114, Pl.’s App., 362–63. Following the April presentation, Opalich, Radcliff, and Kepler continued working on this hospice business plan and financial model (the “Hospice Business Plan”). Doc. 113, Pl.’s Resp. Br., 5; Doc. 114, Pl.’s App., 21–24. Kepler again invoiced this work to EHO. Doc. 113, Pl.’s Resp. Br., 5; Doc. 114, Pl.’s App., 362–63. After Radcliff presented the Hospice Business Plan to the board in June, the board offered Radcliff the role of Executive Vice President of EHO’s hospice division.

Doc. 113, Pl.’s Resp. Br., 6; Doc. 114, Pl.’s App., 192. Radcliff’s offer letter stated that she would be paid commissions on “the gross margin of all new business directly attributable to [her] efforts,” and EHO would use the Hospice Business Plan “as the basis for new growth.” Doc. 114, Pl.’s App., 425–26. Radcliff then traveled to Austin, Texas to meet with EHO’s board. Id. at 193. Radcliff claims that, while she was in Austin, she notified the board that she would continue to consult for

KemPharm as an EHO employee. Doc. 106, Defs.’ Br. Supp., 13; Doc. 114, Defs.’ App., 137–38. EHO contests this and claims Radcliff told the board “her consulting agreement was expiring and she would no longer be consulting for KemPharm after she joined EHO.” Doc. 114, Pl.’s App., 317–19, 347. Further, EHO states it would not have hired Radcliff had it known she intended to continue working for KemPharm. See id. at 347–48. After Radcliff’s trip to Austin, EHO sent her an employment agreement (the “Radcliff Agreement”), which she signed on July 8, 2020. Id. at 195–204. The Radcliff Agreement included several restrictive covenants governing Radcliff’s actions. Radcliff was to “devote [her] full business energies, interest, abilities and productive time to the proper and efficient performance of [her] duties.” Id. at 195. She could not “acquire, assume or

participate in . . . any position, investment or interest . . . adverse or antagonistic to [EHO] . . . or any company, person, or entity . . . in competition with . . . [EHO].” Id. Further, the Radcliff Agreement included confidentiality and non-solicitation provisions similar to those in the Opalich Agreement. Id. at 196, 201–02. Upon hiring Radcliff, EHO began pursuing the strategies highlighted in the Hospice Business Plan. Capital City/Queen City, hospice organizations identified in the Hospice Business Plan, inquired about EHO’s pricing for hospice-related drugs. Id. at 25–26. Capital City/Queen

City provided documentation on their current vendor’s pricing, which EHO used to create “reprice” spreadsheets and a PowerPoint presentation (the “Reprice Spreadsheets”), indicating what it would charge for similar services. Id. Capital City/Queen City and EHO did not have a nondisclosure agreement in place when this information was exchanged. Id. at 26. EHO also pursued the business of Ohio Health Hospice & Palliative Medicine (“Ohio Health”). Doc. 113, Pl.’s Resp. Br., 9; Doc. 114, Pl.’s App., 386. EHO engaged a consulting company called Profero to

prepare a proposal for Ohio Health’s business (the “Ohio Health Proposal”). Doc. 114, Pl.’s App., 386. However, EHO did not win Ohio Health’s business. Id. Later, in August 2020, Opalich engaged a long-time acquaintance, Stephen Greene of Crevice Capital Partners, LLC (“Crevice”), to discuss potentially investing in EHO. Doc. 107, Defs.’ App., 200. Crevice and EHO eventually entered into a nondisclosure agreement, and Opalich began providing EHO’s confidential information to Greene. Id. at 200–02. However, the parties dispute whether Opalich provided Greene with confidential information prior to the execution of the nondisclosure agreement. See Doc. 106, Defs.’ Br. Supp., 17–18; Doc. 113, Pl.’s Resp. Br., 9–10. EHO also claims Opalich caused EHO to enter into the nondisclosure agreement without prior approval from the board. Doc. 113, Pl.’s Resp. Br., 10; Doc. 114, Pl.’s App., 296–98.

B. EHO Terminates Opalich On September 15, 2020, EHO terminated Opalich’s employment. Doc. 114, Pl.’s App., 301. EHO stated several reasons for his termination. First, EHO alleges Opalich had been “belligerent and rude to EHO’s board members.” Id. at 301–05.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Little v. Liquid Air Corp.
37 F.3d 1069 (Fifth Circuit, 1994)
Ragas v. Tennessee Gas Pipeline Co.
136 F.3d 455 (Fifth Circuit, 1998)
Smith v. EMC Corporation
393 F.3d 590 (Fifth Circuit, 2004)
Gonzalez v. Denning
394 F.3d 388 (Fifth Circuit, 2004)
Erie Railroad v. Tompkins
304 U.S. 64 (Supreme Court, 1938)
Hanna v. Plumer
380 U.S. 460 (Supreme Court, 1965)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Bailey v. Shell Western E&P, Inc.
609 F.3d 710 (Fifth Circuit, 2010)
Abraxas Petroleum Corp. v. Hornburg
20 S.W.3d 741 (Court of Appeals of Texas, 2000)
Fox v. Tropical Warehouses, Inc.
121 S.W.3d 853 (Court of Appeals of Texas, 2004)
Jones v. Blume
196 S.W.3d 440 (Court of Appeals of Texas, 2006)
T-N-T Motorsports, Inc. v. Hennessey Motorsports, Inc.
965 S.W.2d 18 (Court of Appeals of Texas, 1998)
Tenneco Inc. v. Enterprise Products Co.
925 S.W.2d 640 (Texas Supreme Court, 1996)
City of Dallas v. Villages of Forest Hills, L.P., Phase I
931 S.W.2d 601 (Court of Appeals of Texas, 1996)
Spoljaric v. Percival Tours, Inc.
708 S.W.2d 432 (Texas Supreme Court, 1986)
Abetter Trucking Co. v. Arizpe
113 S.W.3d 503 (Court of Appeals of Texas, 2003)
Augat, Inc. v. Aegis, Inc.
565 N.E.2d 415 (Massachusetts Supreme Judicial Court, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
EHO360 LLC v. Opalich, Counsel Stack Legal Research, https://law.counselstack.com/opinion/eho360-llc-v-opalich-txnd-2023.